Weekly Digest – July 2026 Weekly Digest – July 2026 29 June 2026: Enhertu approved in the EU as the first tumor-agnostic HER2-targeted ADC for previously treated HER2 positive metastatic Solid tumors The European Union has approved Enhertu as the […]
Weekly Digest – June 2026 Weekly Digest – June 2026 22 June 2026: SystImmune secures first China approval for Iza-bren in Nasopharyngeal carcinoma Biokin Pharma has received NMPA approval for Iza-bren for the treatment of recurrent or metastatic nasopharyngeal carcinoma […]
Weekly Digest – June 2026 Weekly Digest – June 2026 24 June 2026: U.S. FDA approves Trodelvy for first-line treatment of metastatic TNBC Gilead Sciences has received U.S. FDA approval for Trodelvy as a first-line treatment for adults with unresectable […]
Weekly Digest – June 2026 Weekly Digest – June 2026 23 June 2026: European Commission approves Trodelvy for first-line metastatic TNBC Gilead Sciences has received European Commission approval for Trodelvy as a first-line treatment for adult patients with unresectable locally […]
Weekly Digest – June 2026 Weekly Digest – June 2026 24 June 2026: European Commission approves PADCEV as perioperative treatment for cisplatin-ineligible patients with resectable MIBC Astellas and Pfizer have received European Commission approval for PADCEV in combination with KEYTRUDA […]
Weekly Digest – May 2026 Weekly Digest – May 2026 22 May 2026: Datroway approved in the U.S. as first TROP2-directed ADC for 1L metastatic TNBC patients ineligible for PD-1/PD-L1 inhibitors AstraZeneca and Daiichi Sankyo have secured U.S. FDA approval […]
Weekly Digest – May 2026 Weekly Digest – May 2026 15 May 2026: ENHERTU approved in the US for two new indications for patients with HER2-positive early Breast cancer ENHERTU received two new U.S. FDA approvals in HER2-positive early breast […]
Weekly Digest – May 2026 Weekly Digest – May 2026 21 May 2026: CDSCO approves Astellas’ PADCEV for first-line advanced Bladder cancer treatment Astellas Pharma’s PADCEV has been approved by CDSCO for first-line treatment of locally advanced or metastatic urothelial […]
